Lynne M. Smith, MD
Investigator, The Lundquist Institute
Professor and Chair, Department of Pediatrics, Harbor-UCLA Medical Center
Professor of Pediatrics, David Geffen School of Medicine at UCLA
Associate Director, Clinical and Community Research Resources Program, UCLA Clinical and Translational Science Institute at The Lundquist Institute at Harbor UCLA
Understanding the effects of perinatal stress on the developing brain
Research DescriptionUsing neuroimaging techniques as well as neurocognitive and neurodevelopmental assessments, Dr. Smith has worked extensively with children exposed to drugs prenatally including as a co-investigator for the Infant Development Environment and Lifestyle (IDEAL) study, a multicenter, longitudinal study determining the effects of prenatal methamphetamine exposure on children up to age 11 years. Further she has served as an investigator on the Neonatal Neurobehavior and Outcomes in Very Preterm Infants (NOVI) study, a multicenter, longitudinal study exploring what factors make infants born <30 weeks post menstrual age at greatest risk for impaired development. Currently Dr. Smith is a co-investigator for the Environmental influences on Child Health Outcomes (ECHO) Program which seeks to address the impact of environmental influences on child development and health.
Dr. Smith’s ability to work effectively with vulnerable populations as well as to work cooperatively in multi-site collaborations is exemplified by her work as a co-investigator for the UCLA Clinical and Translational Science Institute (CTSI) for the Integrating Special Populations Program (ISP). The ISP focuses on three groups: children, older adults, and groups affected by health disparities, groups prioritized due to their poor health status in Los Angeles and nationally.
- BS, 1986, University of California, Irvine
- MD, 1990, University of California, Davis
Recent and/or Significant Publications
Smith LM, Chang L, Yonekura ML, Grob C, Osborn D, Ernst T. Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero. Neurology. 2001;57(2):255-260. doi:10.1212/wnl.57.2.255
Smith LM, LaGasse LL, Derauf C, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006;118(3):1149-1156. doi:10.1542/peds.2005-2564
Smith LM, Paz MS, LaGasse LL, et al. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012;29(6):515-522. doi:10.1002/da.21956
Smith LM, Diaz S, LaGasse LL, et al. Developmental and behavioral consequences of prenatal methamphetamine exposure: A review of the Infant Development, Environment, and Lifestyle (IDEAL) study. Neurotoxicol Teratol. 2015;51:35-44. doi:10.1016/j.ntt.2015.07.006
Rie Sakai-Bizmark R,Webber EJ, Estevez DA, Murillo M, Marr EH, Smith LM. Healthcare Utilization Due to Substance Abuse among Homeless and Non-Homeless Children and Young Adults in New York. Psychiatric Services. In Press.
Additional Publications on